Tran Khanh T M, Gavitt Tyler D, Le Thinh T, Graichen Adam, Lin Feng, Liu Yang, Tulman Edan R, Szczepanek Steven M, Nguyen Thanh D
Department of Biomedical Engineering University of Connecticut 181 Auditorium Road Storrs 06269 USA.
Department of Pathobiology and Veterinary Science Center of Excellence for Vaccine Research University of Connecticut 61 North Eagleville Road Storrs 06269 USA.
Adv Mater Technol. 2022 Oct 30:2200905. doi: 10.1002/admt.202200905.
The necessity for multiple injections and cold-chain storage has contributed to suboptimal vaccine utilization, especially in pandemic situations. Thermally-stable and single-administration vaccines hold a great potential to revolutionize the global immunization process. Here, a new approach to thermally stabilize protein-based antigens is presented and a new high-throughput antigen-loading process is devised to create a single-administration, pulsatile-release microneedle (MN) patch which can deliver a recombinant SARS-CoV-2 S1-RBD protein-a model for the COVID-19 vaccine. Nearly 100% of the protein antigen could be stabilized at temperatures up to 100 °C for at least 1 h and at an average human body temperature (37 °C) for up to 4 months. Arrays of the stabilized S1-RBD formulations can be loaded into the MN shells via a single-alignment assembly step. The fabricated MNs are administered at a single time into the skin of rats and induce antibody response which could neutralize authentic SARS-CoV-2 viruses, providing similar immunogenic effect to that induced by multiple bolus injections of the same antigen stored in conventional cold-chain conditions. The MN system presented herein could offer the key solution to global immunization campaigns by avoiding low patient compliance, the requirement for cold-chain storage, and the need for multiple booster injections.
多次注射和冷链储存的必要性导致疫苗利用率欠佳,尤其是在疫情期间。热稳定且单次给药的疫苗极有可能彻底改变全球免疫进程。在此,我们提出了一种热稳定基于蛋白质的抗原的新方法,并设计了一种新的高通量抗原加载工艺,以创建一种单次给药、脉冲释放的微针(MN)贴片,该贴片可递送重组严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域(S1-RBD)蛋白——一种用于2019冠状病毒病(COVID-19)疫苗的模型。近100%的蛋白质抗原可在高达100℃的温度下稳定至少1小时,并在人体平均体温(37℃)下稳定长达4个月。通过单次对齐组装步骤,可将稳定化的S1-RBD制剂阵列加载到MN壳中。将制备好的MN一次性施用于大鼠皮肤,可诱导产生能中和真实SARS-CoV-2病毒的抗体反应,提供与在传统冷链条件下储存的相同抗原多次推注诱导的免疫效果相似的免疫效果。本文介绍的MN系统可通过避免患者依从性低、冷链储存要求以及多次加强注射的需求,为全球免疫运动提供关键解决方案。